Immunotech Biopharm Ltd
Status: Publicly traded
Direct answer
Immunotech Biopharm Ltd is publicly traded on HKSE under the ticker 6978.HK.
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the...
Can you invest in Immunotech Biopharm Ltd?
Yes. Immunotech Biopharm Ltd trades publicly on HKSE as 6978.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immunotech Biopharm Ltd
Detailed equity research is provided by MarketSnap.